Jyong Biotech CEO reports 25.35M shares on Form 3
Jyong Biotech Ltd. CEO Fu-Feng Kuo filed an initial Form 3 reporting indirect beneficial ownership of 25,349,500 ordinary shares of the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Jyong Biotech Ltd. CEO Fu-Feng Kuo filed an initial Form 3 reporting indirect beneficial ownership of 25,349,500 ordinary shares of the company. These shares are held through Perfect Minds Co., Ltd., which is ultimately owned via The Innovation Trust, where Ms. Kuo has authority over voting and investment decisions.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
KUO FU-FENG
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 25,349,500 shares (Indirect, Held through Perfect Minds Co., Ltd, a Seychelles company.)
Footnotes (1)
- F1. 25,349,500 ordinary shares are held by Perfect Minds Co., Ltd., a Seychelles company ("Perfect Minds"), which is wholly owned by Innovation Global Group Limited, a British Virgin Islands company, which is wholly owned by The Innovation Trust, a discretionary trust, (the "Trust"). The Trust is managed by Unity Trust Limited, as the trustee. Ms. Fu-Feng Kuo is the Settlor, Appointor and one of the eligible beneficiaries of the Trust. Ms. Fu-Feng Kuo is also the sole director of Perfect Minds and has sole voting and sole dispositive power over the 25,349,500 ordinary shares by virtue of her authority to direct voting and investment decisions with respect to the securities held by Perfect Minds. Accordingly, Ms. Fu-Feng Kuo may be deemed to beneficially own 25,349,500 ordinary shares.
Key Figures
Indirectly owned shares: 25,349,500 ordinary shares
1 metrics
Indirectly owned shares
25,349,500 ordinary shares
Beneficially owned through Perfect Minds and The Innovation Trust
Key Terms
Form 3, beneficially own, discretionary trust, voting and dispositive power, +1 more
5 terms
Form 3 regulatory
"CEO Fu-Feng Kuo filed an initial Form 3 reporting indirect beneficial ownership"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficially own financial
"Accordingly, Ms. Fu-Feng Kuo may be deemed to beneficially own 25,349,500 ordinary shares."
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
discretionary trust financial
"The Innovation Trust, a discretionary trust, (the "Trust")."
voting and dispositive power financial
"has sole voting and sole dispositive power over the 25,349,500 ordinary shares"
indirect ownership financial
"Held through Perfect Minds Co., Ltd, a Seychelles company."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Jyong Biotech (MENS) CEO Fu-Feng Kuo report on this Form 3?
The Form 3 reports that CEO Fu-Feng Kuo beneficially owns 25,349,500 ordinary shares of Jyong Biotech Ltd. These are held indirectly through Perfect Minds Co., Ltd. and an associated trust structure where she controls voting and investment decisions.
Does the Jyong Biotech (MENS) Form 3 show any recent insider buying or selling?
No transactions are reported; this Form 3 reflects existing holdings only. It lists 25,349,500 ordinary shares indirectly owned by CEO Fu-Feng Kuo through Perfect Minds Co., Ltd., without indicating any new purchases, sales, or option exercises.
Why is Fu-Feng Kuo considered a more than 10% owner of Jyong Biotech (MENS)?
Ms. Kuo may be deemed to beneficially own 25,349,500 ordinary shares, giving her more than 10% ownership. She holds sole voting and dispositive power over shares owned by Perfect Minds Co., Ltd. through her authority under the related trust structure.
What role does Perfect Minds Co., Ltd. play in Jyong Biotech (MENS) insider ownership?
Perfect Minds Co., Ltd., a Seychelles company, directly holds 25,349,500 ordinary shares of Jyong Biotech. CEO Fu-Feng Kuo is the sole director of Perfect Minds and controls voting and investment decisions, so she is treated as the beneficial owner of these shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates